Skip to main content
Equibles
OMER logo

OMER · Omeros Corp

Track OMER — free

Use OMER with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about OMER

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$17.19 -0.16 (-0.92%) At close · Aug 14
Market Cap
$1.24B
Shares
72.39M

Omeros Corp Earnings Call Transcripts

Every quarterly earnings call for Omeros Corp (OMER) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$33.46M '25 Q1 25-05-15 · $ −$25.42M '25 Q2 25-08-14 · $9.89M $56.06M '26 Q1 26-05-13 LATEST · $28.53M $13.23M '26 Q2 26-08-12
Earnings call
FY26 · Q2
2026-08-12
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Revenue
$28.53M
Diluted EPS
$0.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Omeros Corp Q1 FY2026 Earnings Call
Confident tone Yartemlia Launch and Commercial Uptake Reimbursement and CMS Coding Novo Nordisk / Zaltanabar Transaction
Revenue
$9.89M
Diluted EPS
$0.62
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-31
Omeros Corp Q4 FY2025 Earnings Call
Confident tone Yartemlia / narsoplimab FDA approval and launch Novo Nordisk / Zaltenabar deal Transplant center formulary / P&T committee adoption
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Omeros Corp Q3 FY2025 Earnings Call
Confident tone Yartemlia (narsoplimab) FDA Approval and Commercial Launch Operating Expenses and 2026 Outlook Novo Nordisk Asset Purchase Deal (sultanobar/MASP-3)
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Omeros Corp Q2 FY2025 Earnings Call
Confident tone Narsoplimab BLA review and PDUFA Commercial launch readiness Balance sheet restructuring and financing
Revenue
$
Diluted EPS
$-0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Omeros Corp Q1 FY2025 Earnings Call
Positive tone Narsoplimab FDA approval and launch Zaltenibart PNH program Balance sheet and liquidity management
Revenue
$
Diluted EPS
$-0.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Omeros Corp Q4 FY2024 Earnings Call
Confident tone Narsoplimab BLA resubmission for TA-TMA Zaltenibart and OMS1029 pipeline European MAA submission
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Omeros Corp Q3 FY2024 Earnings Call
Positive tone Zaltenibart (OMS906) Phase 2/3 Development Phase 3 Study Design and Enrollment OMIDRIA Commercial Expansion
Diluted EPS
$-0.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Omeros Corp Q2 FY2024 Earnings Call
Diluted EPS
$-0.97
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Omeros Corp Q1 FY2024 Earnings Call
Positive tone OMS906 PNH clinical program Narsoplimab BLA / FDA resubmission OMIDRIA royalty / financial results
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Omeros Corp Q4 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Omeros Corp Q3 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Omeros Corp Q2 FY2023 Earnings Call
Diluted EPS
$-0.59
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Omeros Corp Q1 FY2023 Earnings Call
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-13
Omeros Corp Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Omeros Corp Q3 FY2022 Earnings Call
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Omeros Corp Q2 FY2022 Earnings Call
Diluted EPS
$-0.49
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Omeros Corp Q1 FY2022 Earnings Call
Diluted EPS
$-0.53
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Omeros Corp Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Omeros Corp Q3 FY2021 Earnings Call
Revenue
$30.00M
▲ 14.9% YoY
Diluted EPS
$-0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Omeros Corp Q2 FY2021 Earnings Call
Revenue
$28.82M
▲ 113% YoY
Diluted EPS
$-0.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Omeros Corp Q1 FY2021 Earnings Call
Revenue
$21.06M
▼ 10.5% YoY
Diluted EPS
$-0.57
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Omeros Corp Q4 FY2020 Earnings Call
Revenue
$10.63M
▼ 68.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Omeros Corp Q3 FY2020 Earnings Call
Revenue
$26.11M
▼ 12.5% YoY
Diluted EPS
$-0.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Omeros Corp Q1 FY2020 Earnings Call
Revenue
$23.54M
▲ 8.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-02
Omeros Corp Q4 FY2019 Earnings Call
Revenue
$33.42M
▲ 51.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–26 of 26 earnings calls
Key facts CIK 1285819 CUSIP 682143102 13F (30d) 174 filings 167 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)